# A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

Source: https://onco.cc/trials/nct02448173/  
OnCo record `nct02448173` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Vaccinogen Inc, not yet recruiting.

## Summary

A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer is a phase 3, randomised interventional study registered as NCT02448173 by Vaccinogen Inc, with a registry enrolment figure of 550 participants, started 2026-08 and due to reach its primary completion in 2031-08. Interventions recorded: OncoVAX and Surgery; Surgery. Conditions listed: Stage II Colon Cancer. Primary outcome: Disease-Free Survival. Colorectal eligibility wording from the registry: "* Patients with more than one malignant primary colon cancer will be excluded". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT02448173
- Phase: 3
- Setting: A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
- Sponsor: Vaccinogen Inc
- Enrolled: 550

## Sources

- ClinicalTrials.gov NCT02448173: https://clinicaltrials.gov/study/NCT02448173

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct02448173.json